Malignant tumor of lung (disorder)
Clinical Trial: ARCADIAN
Year Started: 2021
A phase I dose escalation study to investigate combining the antimalarial drug atovaquone with chemoradiotherapy in non-small cell lung cancer, using a time to event continual reassessment method (TiTE CRM).
- Access:
- Access restricted at present
- Type:
- Clinical Trial
- Status:
- In progress
- Consent restrictions:
- No restrictions
| Associated Data Type | Procurement Timeframe |
|---|---|
| Biomarker datasets | > 6 months |
| Followup records | > 6 months |
| Imaging data | > 6 months |
| Physiological/biochemical measurements | > 6 months |
| Treatment records | > 6 months |
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Plasma | -60°C to -85°C | Not applicable | 75% -99% |
Female
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | RT | Paraffin | Not applicable | 75% -99% |
Male
Adult (> 40 years)
1 - 10 donors
| Material Type | Extraction Procedure | Storage Temperature | Preservation Type | Macroscopic Assessment | % of Sample Set |
|---|---|---|---|---|---|
| Tissue specimen | RT | Paraffin | Not applicable | 75% -99% |